Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

Abstract Isatuximab is an approved anti‐CD38 monoclonal antibody with multiple antitumor modes of action. An exposure‐response (E‐R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clinical study who received isatuximab at doses from 5 to 20 ...

Full description

Bibliographic Details
Main Authors: Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu, Bernard Sebastien, Hoai‐Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat‐Follet, Dorothée Semiond
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12789

Internet

https://doi.org/10.1002/psp4.12789

Similar Items